Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This study aims to generate clinical data on the efficacy, safety, and tolerability of
rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia
(PCP) in adults living with human immunodeficiency virus (HIV), which would expand the
knowledge of clinical use of rezafungin.
Phase:
Phase 2
Details
Lead Sponsor:
Mundipharma Research Limited
Treatments:
Rezafungin Trimethoprim, Sulfamethoxazole Drug Combination